(SOLV) Solventum - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US83444M1018
SOLV: Medical Supplies, Dental Products, Software Solutions, Purification
Solventum Corporation (NYSE:SOLV), a healthcare company, specializes in developing, manufacturing, and commercializing a diverse range of solutions to address critical customer and patient needs globally. Incorporated in 2023 and headquartered in Maplewood, Minnesota, Solventum operates across four key segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Each segment is strategically positioned to capitalize on growing market demands and technological advancements.
The Medsurg segment offers a comprehensive suite of products, including negative pressure wound therapy, advanced wound dressings, and medical technologies for OEMs, addressing the increasing demand for effective wound care solutions driven by an aging population. The Dental Solutions segment provides orthodontic products like clear aligners, aligning with the trend towards discreet orthodontic treatments. The Health Information Systems segment delivers digital solutions, riding the wave of healthcares digital transformation. The Purification and Filtration segment offers technologies addressing water and air quality concerns, a growing priority globally.
Solventum distributes its products through multiple channels, ensuring wide market reach and accessibility. The companys recent incorporation in 2023 positions it as a dynamic player in the healthcare industry, leveraging its diverse portfolio to drive growth and innovation.
Additional Sources for SOLV Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SOLV Stock Overview
| Market Cap in USD | 11,683m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception | 2024-03-26 |
SOLV Stock Ratings
| Growth Rating | -7.25 |
| Fundamental | 16.3 |
| Dividend Rating | 0.0 |
| Rel. Strength | -0.26 |
| Analysts | 3.09/5 |
| Fair Price Momentum | 56.02 USD |
| Fair Price DCF | 102.27 USD |
SOLV Dividends
No Dividends PaidSOLV Growth Ratios
| Growth Correlation 3m | -51.1% |
| Growth Correlation 12m | 72.4% |
| Growth Correlation 5y | 65.9% |
| CAGR 5y | -15.87% |
| CAGR/Max DD 5y | -0.40 |
| Sharpe Ratio 12m | -0.23 |
| Alpha | -6.68 |
| Beta | 0.511 |
| Volatility | 32.97% |
| Current Volume | 574.7k |
| Average Volume 20d | 920.6k |
As of April 30, 2025, the stock is trading at USD 66.25 with a total of 574,687 shares traded.
Over the past week, the price has changed by +2.02%, over one month by -12.87%, over three months by -11.07% and over the past year by +0.52%.
Neither. Based on ValueRay Fundamental Analyses, Solventum is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 16.27 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SOLV as of April 2025 is 56.02. This means that SOLV is currently overvalued and has a potential downside of -15.44%.
Solventum has received a consensus analysts rating of 3.09. Therefor, it is recommend to hold SOLV.
- Strong Buy: 1
- Buy: 0
- Hold: 9
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, SOLV Solventum will be worth about 60.5 in April 2026. The stock is currently trading at 66.25. This means that the stock has a potential downside of -8.68%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 80.9 | 22.1% |
| Analysts Target Price | 80.9 | 22.1% |
| ValueRay Target Price | 60.5 | -8.7% |